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Deep venous thrombosis and its subsequent
sequelae of pulmonary embolism, chronic venous
insufficiency, or both remain significant medical prob-
lems in our society. It has been estimated that
260,000 people each year are hospitalized in acute-
care facilities for the treatment of venous thrombosis-
related illness.1 Previous work from our laboratory
has demonstrated that venous thrombosis contributes
to an active vein wall inflammatory response that is
initiated and propagated by further thrombosis.2 This
response is characterized by early vein wall neutrophil
infiltration followed by monocyte/macrophage infil-
tration. Although the exact mechanism that governs
the thrombosis/vein wall inflammatory response has
not been fully elucidated, there appears to be a com-
plex regulatory mechanism, involving a balance
between pro-inflammatory and anti-inflammatory
vein wall cytokines, that regulates the intensity of the
inflammatory response.3 Concomitantly, platelet and
endothelial cell derived adhesion molecules con-
tribute to the initial reversible and subsequent irre-
versible influx and binding of these vein wall inflam-
matory cells to the endothelium, further propagating
the inflammatory response.4
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Purpose: Venous thrombosis results in a vein wall inflammatory response initiated by
thrombus. Although anticoagulation with standard heparin (SH) and low–molecular-
weight heparin (LMWH) is known to limit further thrombosis, their anti-inflammato-
ry properties are poorly defined. The anti-inflammatory properties of these heparins
were studied.
Methods: Sprague-Dawley rats were divided into groups and underwent inferior vena
caval (IVC) ligation just below the renal level producing IVC thrombosis. One hour
before ligation, animals received subcutaneous SH or LMWH at either high or low dose;
normal saline (NS) was used as control. Six hours after ligation, animals were killed, and
the IVCs were analyzed for clot presence, vein wall morphometrics, and vein wall per-
meability (VP) to define injury.
Results: Animals in both low-dose groups had no measurable anticoagulation, whereas
those in both high-dose groups were adequately anticoagulated. There were statistically
less IVC neutrophils for all groups compared with the control group, with low-dose
LMWH showing the least cells (low-dose LMWH, 16 ± 3; high-dose LMWH, 37 ± 10;
low-dose SH, 37 ± 6; high-dose SH, 32 ± 9; NS control, 63 ± 2). Similar results were
noted for total inflammatory cells. The lowest VP was noted for low-dose LMWH.
Conclusion: Although both SH and LMWH inhibited vein wall neutrophils and total
inflammatory cells, low-dose LMWH was most effective limiting neutrophil extravasa-
tion and was the only intervention to decrease VP below control levels. This occurred
without preventing thrombus formation or causing a state of anticoagulation. Low-dose
LMWH possesses anti-inflammatory properties distinct from its anticoagulant proper-
ties. (J Vasc Surg 1998;28:848-54.)
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Heparin is the anticoagulant traditionally used for
the treatment of thromboembolic disease. It is known
to possess multiple actions, including potent antico-
agulant, antithrombotic, and antiplatelet activity.5-7
Heparin also possesses anti-inflammatory activity that
contributes to the relief of spasm and pain associated
with thrombus propagation.8,9 However, despite
these findings, its vein wall anti-inflammatory activity
has been poorly characterized. Characterized even less
well is the anti-inflammatory activity for heparin frac-
tions known as low–molecular-weight heparins.
Therefore, in a well-described rodent model of stasis-
induced venous thrombosis,2 we set out to better
define the anti-inflammatory effects of standard
unfractionated heparin (SH) and low–molecular-
weight heparin (LMWH) in the setting of thrombus-
induced vein wall inflammation.
In this study, using both low and high doses of
SH and LMWH, we found that both SH and
LMWH significantly decreased the vein wall inflam-
matory response associated with stasis-induced
venous thrombosis. Importantly, LMWH, at non-
anticoagulant dosing, was the most effective, pos-
sessing anti-inflammatory properties that were sepa-
rate from its anticoagulant activity.
MATERIALS AND METHODS
Animal model and tissue analysis. Sprague-
Dawley rats (n = 96), weighing 250 to 300 grams,
were randomly allocated to 5 separate groups and
underwent inferior vena caval (IVC) ligation just
below the level of the renal veins, as previously
described.2 In each group of animals, 6 underwent
morphometric analysis, 6 underwent vein wall perme-
ability studies, and 6 underwent thrombus weight
analysis (except for the control group, in which an
additional 6 underwent thrombus weight evaluation).
Coagulation analysis was performed on those animals
studied with morphometries and thrombus weight
determinations in each group, including the addition-
al 6 control rats noted above.
Animals were anesthetized by means of inhala-
tion of isoflurane (1% to 2%) and oxygen (100%).
Aseptic midline laparotomy was performed, and the
thrombus was induced by ligating the IVC just
below the level of the renal veins with concomitant
ligation of IVC draining side branches. One hour
before ligation, the animals within a group received
a single subcutaneous injection into the abdominal
wall of either high-dose SH (450 U/kg; Elk-Sinn,
Cherry Hill, NJ), low-dose SH (300 U/kg), high-
dose LMWH (450 anti-Xa U/kg; Fragmin,
Pharmacia & Upjohn, Kalamazoo, Mich), or low-
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dose LMWH (100 anti-Xa U/kg). These doses of
anticoagulants were chosen from previous studies in
rats so the high dose would produce an anticoagu-
lant effect, whereas the low dose would result in no
measurable anticoagulant effect. A final group
received normal saline (NS) subcutaneous injection
at an equivalent volume 1 hour before ligation and
served as a control group.
We began documenting the baseline level of rat
serum anticoagulation by determining activated par-
tial thromboplastin time (aPTT), thrombin clotting
time (TCT), and anti-factor-Xa activity in NS-treat-
ed animals. Six hours after thrombus induction and
while the rats were under general anesthesia, blood
was drawn from the tail veins of the experimental
animals, and the degree of serum anticoagulation
was determined just before the rats were killed.
Animals receiving SH underwent aPTT and TCT
assays, whereas those undergoing LMWH treatment
were monitored by means of aPTT, TCT, and anti-
factor Xa assays. Control animals also underwent
aPTT, TCT, and anti-factor Xa assays. All animals
were subsequently killed under isoflurane anesthesia,
and the infrarenal IVC below the ligature site was
harvested, weighed, and grossly examined for the
presence of thrombus. The harvesting of the IVC
occurred simultaneously with or just before death.
Vein wall specimens were used for either morpho-
metric evaluation (n = 6) or vein wall permeability (n
= 6) as a marker of vein wall injury.
Coagulation analysis. The aPTT assays were
performed on 0.1 mL platelet-rich plasma with 0.1
mL rabbit cephaloplastin (Baxter, Miami, Fla) and 0.1
mL of 0.02 mol/L CaCl2 added as an activator on a
fibrometer (Baxter). TCT samples were measured on
a fibrometer with 0.02 mL platelet-rich plasma and
0.1 mL TCT reagent (American Dade, Miami, Fla).
The aPTT and TCT measurements were performed
in duplicate, and the results were averaged.
Anti-factor Xa measurements were performed
after cold centrifugation (3000 rpm for 20 minutes at
4°C) of citrated blood stored on ice after collection.
In the anti-factor Xa assay (Coatest Heparin, KB
Virtum, Stockholm, Sweden), excess antithrombin,
followed by factor Xa, was added to the plasma sam-
ple, which was then reacted with a chromogenic sub-
strate S-2222.10 Anti-factor Xa activity was inversely
proportional to absorbency at 405 nm, which indi-
cated the quantity of remaining uninhibited factor
Xa, as a measure of residual LMWH activity.
Concentrations were then determined from standard
curves constructed from known amounts of LMWH
and their corresponding absorbencies for the assay.
Histopathologic analysis and leukocyte mor-
phometric analysis. For vein wall specimens
undergoing vein wall morphometric analysis, the
intact vein wall and clot was fixed in 10% formalde-
hyde for 24 hours and then placed into a 70% alco-
hol solution for subsequent staining with hema-
toxylin and eosin. Leukocyte vein wall trafficking
and emigration analysis was performed by means of
standard histologic analysis and morphometrics, as
previously described.2,3 After staining the paraffin-
embedded slides with hematoxylin and eosin, mor-
phometric analysis was performed under high power
(oil emersion) light microscopy by counting each
section of tissue for various inflammatory cell types.
Each vein wall was assessed for the number and type
of cells, including the thrombus vein wall interface
and extending the width of 1 high power field
(HPF, 1000· ). Five HPF sections of each vein wall
were analyzed. Cells were classified as neutrophils,
monocytes or lymphocytes with standard morpho-
logic criteria, including cell size, cytoplasm content,
and nuclear size. Morphometric analysis has been
previously correlated to cell type by means of
immunohistochemical staining.3
Vein wall permeability. This technique was used
to evaluate vein wall injury in response to stasis-
induced venous thrombosis. Microvascular perme-
ability was measured with a modification of a previ-
ously described technique.11-14 Animals received 20
mg/kg of Evan’s blue dye (Sigma Chemical, St.
Louis, Mo) through tail vein injection 3 hours before
being killed. When the rats were killed, the IVC
length and weight was determined, then the throm-
bus was separated from the vein wall. Additionally,
when the rats were killed, a heparinized blood sample
was taken from the IVC, and blood cells were
removed by means of centrifugation. After homoge-
nizing the vein wall specimen for 10 seconds · 3 in
phosphate buffered saline (PBS), the specimens were
incubated at 60°C in formamide for 18 hours.
Thereafter, the supernatant was separated by means of
centrifugation at 5000 rpm for 30 minutes. Three
IVC vein wall specimens were combined and pooled
for analysis. Evan’s blue in the supernatant was quan-
titated by means of dual wavelength spectrophoto-
metric analysis at 620 nm and 740 nm. This method
allows for correction of the absorbency of contami-
nating heme pigments with the following formula:
corrected absorbency at 620 nm = actual absorbency
at 620 nm – [1.426 (absorbency at 740 nm) + 0.03].
Vein wall permeability results were expressed as a ratio
of absorbency of Evan’s blue in the vein wall, normal-
ized to length, compared with that in the blood.
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Statistical evaluation and animal use. Mean ±
SE and unpaired Student t test comparing experi-
mental groups with control groups were used when
appropriate. To determine if differences existed
within treatment groups, 1-tailed analysis of variance
(ANOVA) was performed. Individual t tests between
groups were performed if ANOVA values suggested
differences between the 5 groups. Significance was
defined at a level of P ≤ .05.
All animals used in this study were housed and
cared for in the University of Michigan Unit for
Laboratory Animal Medicine under the direction of
a licensed veterinarian according to the “Principles of
Laboratory Animal Care” (formulated by the
National Society for Medical Research) and Guide
for the Care and Use of Laboratory Animals (National
Institutes of Health [NIH] Publication No. 86-23,
revised 1985). The protocol was approved by the
University of Michigan Committee on the Use and
Care of Animals.
RESULTS
Clot presence was lowest in the high-dose
LMWH group. All animals underwent successful
infrarenal IVC ligation. However, the high-dose
LMWH group revealed a lower number of IVCs
with clot (13 of 18 specimens positive for clot) as
compared with the NS-treated animals (18 of 18
specimens positive for clot), low-dose LMWH
group, high-dose SH group, and low-dose SH
group (17 of 18 specimens positive for clot).
Thrombi in both LMWH groups were grossly small-
er than those in the SH or control groups.
Thrombus weight was lowest in the LMWH-
treated animals. Thrombus weight in the NS con-
trols averaged 53.9 ± 5.1 mg (n = 12), whereas in
the high-dose SH and low-dose SH groups the
thrombus weight averaged 60.6 ± 4.8 mg (n = 6)
and 51.5 ± 3.1 mg (n = 6), respectively. In the high-
dose LMWH and low-dose LMWH groups, these
weights were 24.4 ± 5.6 mg (n = 6) and 39.8 ± 2.9
mg (n = 6), respectively. Significant differences
between groups were found by ANOVA (P < .01),
and high-dose LMWH weight was significantly dif-
ferent from all other groups (P < .05). Low-dose
LMWH was also significantly different from both
high-dose SH and low-dose SH (P < .05).
Adequate anticoagulation was achieved in
animals treated with both high-dose SH and
high-dose LMWH. Six hours after thrombus initi-
ation, the rat serum anticoagulation profile (Table I)
revealed little anticoagulation in the animals treated
with low-dose SH, as compared with the NS-treated
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group (low-dose SH aPTT 15.5 ± 0.6 seconds, TCT
22.3 ± 1.4 seconds; NS aPTT 12.3 ± 1.7 seconds,
TCT 20.8 ± 1.0 seconds). However, at 6 hours, ani-
mals treated with high-dose SH were adequately
anticoagulated (high-dose SH aPTT 51.8 ± 9.6 sec-
onds, TCT 43.6 ± 8.4 seconds). Animals treated
with low-dose LMWH revealed no anticoagulation
via anti-factor-Xa activity, as compared with the NS-
treated animals (NS = 0.32 IU/mL vs. Low-Dose
LMWH = 0.30 IU/mL). However, animals treated
with high-dose LMWH demonstrated adequate
anticoagulation at 6 hours (high-dose LMWH =
1.09 IU/mL).
Vein wall inflammation, as assessed by mor-
phometrics, was significantly less in anticoagu-
lant-treated animals than NS controls (Fig 1).
Differences by ANOVA were found between groups
for neutrophils (P < .01) and total inflammatory
cells (P < .01). The total leukocyte count of the
infrarenal IVC wall in NS-treated animals revealed
82 ± 3 inflammatory cells per 5 HPF, with an
absolute differential of 63 ± 2 neutrophils, 18 ± 1
monocytes, and 1 ± 1 lymphocytes (n = 6) (Table
II). In the animals treated with high-dose SH, there
was a 49% decrease in neutrophils (P < .01) and a
38% decrease in the total inflammatory cell count (P
< .05). Animals treated with low-dose SH and high-
dose LMWH also had a significant decrease in vein
wall neutrophils (P < .01, P < .05) and total inflam-
matory cells (for low-dose SH, P < .01), as com-
pared with the NS-treated animals. However, the
greatest difference in vein wall inflammatory cell
influx was seen in the animals treated with low-dose
LMWH, with 34 ± 3 total inflammatory cells (59%
Fig 1. A, Inferior vena cava (IVC) of a control rat treated with normal saline; note presence
of inflammatory cells (primarily neutrophils) in the IVC wall. B, IVC of a rat treated with high-
dose heparin; note inflammatory cells (primarily neutrophils) at the luminal surface of the IVC
and in the IVC wall. C, IVC of a rat treated with low-dose heparin; inflammatory cells (pri-
marily neutrophils) again noted in IVC wall. D, IVC of a rat treated with high-dose low–
molecular-weight heparin; inflammatory cells primarily at the luminal surface of the IVC. 
E, IVC of a rat treated with low-dose low–molecular-weight heparin; note lack of inflamma-
tory cells at the luminal surface and in the IVC wall. w, wall of IVC; n, neutrophils; t, throm-
bus; arrows point to thrombus-vein wall interface. All 1000· (oil); Hematoxylin and Eosin.
FPO
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decrease; P < .01) and an absolute differential of 16
± 3 neutrophils (75% decrease; P < .01), 17 ± 1
monocytes, and 1 ± 1 lymphocytes.
Vein wall permeability, as a marker of vein
wall injury, was lowest in the animals treated
with low-dose LMWH. Vein wall permeability
was lowest in the low-dose LMWH group, although
differences between the groups were not noted by
ANOVA. The vein wall permeability (expressed in
absorbency units [aU] and normalized to vein wall
length) revealed 0.035 aU in NS-treated animals, as
compared with 0.056 aU in animals treated 
with high-dose SH; 0.051 aU in animals treated
with low-dose SH; 0.040 aU in animals treated with
high-dose LMWH; and 0.025 aU in animals treated
with low-dose LMWH.
DISCUSSION
Since its initial introduction, heparin has been
found to be essential in the treatment of thromboem-
bolic disease and has been suspected of possessing
potent anti-inflammatory activity.8,9 Unfractionated
SH is derived from a complex linear polysaccharide of
60,000 to 100,000 d, which is degraded to a hetero-
geneous mixture of approximately 12,000 d.15
LMWH is isolated from SH by means of gel filtra-
tion chromatography or differential precipitation
with ethanol, and it possesses greater anti-factor Xa
activity than anti-factor IIa activity.15,16 Although
the biologic effects of heparin are multiple, its anti-
inflammatory properties have been poorly defined,
and the anti-inflammatory effects of LMWH are
even less well-defined.
The anti-inflammatory properties of both stan-
dard heparin and LMWH at both high- and low-
dose subcutaneous administration were character-
ized in a rat model of stasis-induced venous throm-
bosis. The rat has been shown to serve as an
appropriate model for investigating the effects of
heparin, with results applicable to humans.17
Current clinical practice targets an aPTT value of 1.5
to 3.0 times baseline values as the goal for adequate
anticoagulation, whereas the ideal dosing for
LMWH has been less clearly defined. In our current
study, adequate anticoagulation was achieved in
both high-dose SH and high-dose LMWH groups.
This was demonstrated with a 6-hour aPTT 4.2 ·
baseline and TCT 2.1 · baseline for the high-dose
SH group and an anti-factor Xa level of 1.09
IU/mL for the high-dose LMWH group. The coag-
ulation profile of both low-dose SH and low-dose
LMWH groups demonstrated no anticoagulation
(Table I). The presence of clot was noted in all treat-
ment groups. However, animals treated with high-
dose LMWH demonstrated the least amount of clot
presence (13 of 18 specimens), as compared with
the remaining treatment groups (17 of 18) and the
control animals (18 of 18). Furthermore, both
Table I. Anticoagulation profile
aPTT (sec) TCT (sec) anti-factor Xa activity (IU/mL)
Normal saline 12.3 ± 1.7 (n = 8) 20.8 ± 1.0 (n = 11) 0.32 ± 0.38 (n = 18)
High-dose SH 51.8 ± 9.6 (n = 9) 43.6 ± 8.4 (n = 12)
Low-dose SH 15.5 ± 0.6 (n = 10) 22.3 ± 1.4 (n = 12)
High-dose LMWH 56.9 ± 13.1(n = 12) 75.8 ± 8.2 (n = 12) 1.09 ± 0.06 (n = 12)
Low-dose LMWH 16.0 ± 3.1 (n = 7) 21.2 ± 1.6 (n = 4) 0.30 ± 0.39 (n = 12)
aPTT, activated partial thromboplastin time; TCT, thrombin clotting time; SH, standard heparin; LMWH, low–molecular-weight heparin.
Table II. Vein wall morphometrics
Neutrophils Monocytes Lymphocytes Total inflammatory cells
Normal saline (n = 6) 63 ± 2 18 ± 1 1 ± 1 82 ± 3
High-dose SH (n = 6) 32 ± 9† 17 ± 3 2 ± 1 51 ± 12*
Low-dose SH (n = 6) 37 ± 6† 13 ± 1 2 ± 1 52 ± 6†
High-dose LMWH (n = 6) 37 ± 10* 18 ± 3 2 ± 1 57 ± 11
Low-dose LMWH (n = 6) 16 ± 3†‡ 17 ± 1 1 ± 1 34 ± 3†‡
*P < .05 (compared with normal saline)
†P <.01 (compared with normal saline)
‡P < .05 (low-dose SH vs. low-dose LMWH)
SH, standard heparin; LMWH, low–molecular-weight heparin.
LMWH-treated groups had qualitatively and quan-
titatively less thrombus as measured by means of
thrombus weight, as compared with the SH-treated
groups. This suggests that LMWH has a greater
antithrombotic effect than SH, even when it did not
prolong any of the coagulation parameters mea-
sured, as seen in the low-dose LMWH group.
Clinically, LMWH has previously been found to sup-
press prothrombin activation more effectively than
unfractionated SH in patients treated for venous
thrombosis.18
Previous work from our laboratory has charac-
terized the vein wall inflammatory response in the
rat during the presence of venous thrombosis.2,3
This response occurs in a predictable leukocyte traf-
ficking scheme, with early neutrophil influx (by 6
hours) and later monocyte/macrophage infiltration
most prominent between 2 and 6 days. Our current
findings demonstrate that SH and LMWH result in
decreased vein wall inflammation, as assessed by
means of morphologic criteria (Table II). The great-
est decrease in vein wall neutrophils was seen with
low-dose LMWH, despite no demonstratable anti-
coagulation, as noted earlier. Both neutrophil mar-
gination at the surface of the vein wall and emigra-
tion into the vein wall were inhibited. This suggests
LMWH may possess anti-inflammatory activity that
is separate from its anticoagulant activity. No differ-
ences in monocytes were noted between groups,
despite heparin’s known ability to bind to the sur-
face of monocytes.19-21 However, because of the
early time-point of evaluation in this study (6
hours), effects on monocytes would not necessarily
be expected.
In addition to its effects on vein wall leukocyte
infiltration, vein wall permeability, as a marker of
vein wall injury, was lowest in the animals treated
with low-dose LMWH and highest in animals treat-
ed with low-dose SH and animals treated with high-
dose SH. In fact, the only group to be below con-
trol value for vein wall permeability was the low-
dose LMWH group. Unfractionated SH has been
associated with increased capillary permeability,
which may be associated with an increased tendency
for microvascular bleeding.22 However, LMWH has
been shown to increase neither capillary permeabili-
ty nor microvascular bleeding.22 Our data supports
these observations, especially at a low, nonanticoag-
ulant dose for LMWH.
The events involved in stasis-induced venous
thrombosis have been previously correlated with the
expression of pro-inflammatory and anti-inflammato-
ry cytokines.3 However, in other studies from our lab-
oratory using vein wall enzyme-linked immunosor-
bent assay protein extraction techniques, neither SH
nor LMWH at high- or low-dose influenced the
expression of vein wall cytokines (data not shown).
This suggests that the anti-inflammatory effects of SH
and LMWH may not be cytokine-mediated.
Finally, SH and LMWH administration are clini-
cally associated with decreased symptoms of pain
and spasm associated with thrombus formation.
However, the specific mechanisms of SH and
LMWH action on vein wall inflammatory inhibition
are not completely understood. A number of
heparin’s anti-inflammatory mechanisms have been
previously proposed, including its ability to inhibit
neutrophil chemotaxis and phagocytosis in vitro,
bind and inhibit various vasoactive products such as
bradykinin and endotoxins that act as neutrophil
chemoattractans,23 inhibit neutrophil aggregation,24
and modulate the activity of a number of inflamma-
tory proteins including cell growth factors, angio-
genic factors, and complement.25,26 In addition,
heparin oligosaccharides have demonstrated binding
to leukocyte adhesion molecules (L- and P-selectins)
and the competitive displacement of pro-adhesive
cytokines from the endothelial cell surface con-
tributing to acute inflammatory inhibition.27,28 Our
results confirm SH anti-inflammatory properties
during stasis-induced venous thrombosis and
demonstrate that LMWH possesses even more
potent anti-inflammatory activity than SH. Such
activity favors the use of LMWH for the treatment
of venous thromboembolic disease.
CONCLUSIONS
Heparin and LMWH limit inflammatory cell
extravasation into the vein wall in association with
venous thrombosis. The greatest vein wall anti-
inflammatory effect was seen with low-dose
LMWH, in which its anti-inflammatory activity is
separate from its measured anticoagulant activity.
For this reason, LMWH may be more effective in
the treatment of venous thrombosis.
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